GLP-1
-
GLP-1新锐IPO，核心管线即将上市
正文共2700字 3图 预计阅读时间8分钟 2025年5 月 27 日，GLP-1新锐派格生物正式登陆港交所，中金公司担任独家保荐人。发行价每股 15.60 港元，发行市值达60.…
-
恒瑞海外NewCo的 GLP-1 公布II期喜报！会是下一个重磅吗？
2024年5月，恒瑞将GLP-1产品组合以1亿美元首付款+1000万美元近期里程碑付款+累计不超过59.25亿美元的里程碑付款+19.9%股权的价格，授权给了当时还名不见经传的Ka…
-
Professor Liping Zhao: Dysbiosis of the core microbiota is the root cause of human obesity！
The video is available for watching, too. Please visit DrugTimes. Many thanks!~
-
【百家争鸣】赵立平教授：核心菌群失调才是人类肥胖的根本原因！
药时代获得赵教授的授权转载，衷心感谢！
-
siRNA Therapeutics Targeting INHBE and another target 【Product for Licensing】
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss 【Product for Licensing】
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Musk’s Hobby Also Sparks a Boom for WuXi AppTec!
For more reports, please follow DrugTimes
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
